Sanj Singh

Welcome to Temple ORTHOBiologics. Preventing scar tissue was once thought impossible. In a single moment, everything changes. An injury strikes, bringing dreams and routines to a sudden halt. Feelings of frustration, isolation, and even anxiety creep in. “How long until I can return?” “Will I be the same?” TX-33 is the flagship product and the first intra-articular drug treatment being developed specifically to prevent scar tissue formation after injury or surgery. Joining Co-Founders Dr. RJ Williams III from HSS in NYC is a world-class team positioned to drive cutting-edge innovations to address the problems stemming from rising volume of knee and other joint injuries and surgeries. For years, the prevention of scar tissue was considered impossible. Temple OrthoBiologics is changing that narrative. United by a shared mission, we are committed to enhancing the lives of everyone who values an active lifestyle, from young children to the boomer generation, and from recreational enthusiasts to elite athletes. While an injury may temporarily sideline you, the promise of TX-33 could significantly improve your recovery, help you come back stronger, and proudly declare, “I’m back™”. #sportsinjuries #ACL #Sportsmedicine #RegenerativeMedicine #orthopedics #SportsInjuryRecovery #TissueRegeneration #AthleteHealth #ScarTissuePrevention #FutureOfSportsMedicine #PerformanceRecovery #AdhesionPrevention #Biomechanics #TechInMedicine #biomaterials #orthobiologics #clinicaltrials